Danaher makes the tools, chemicals, and instruments that scientists and doctors cannot work without. Its three segments, Biotechnology, Life Sciences, and Diagnostics, sell things like cell culture media used to grow biological medicines, reagents used to identify proteins in a lab, and test cartridges used in hospitals to detect diseases. The key to understanding this business is that most of what Danaher sells is not a one-time purchase. A hospital that installs a Cepheid testing machine must keep buying Cepheid test cartridges. A pharmaceutical company that builds a manufacturing process around Cytiva filters must keep ordering those filters. Equipment is the hook. Consumables are the ongoing revenue. The diagram below traces where the money goes.
How Danaher Makes Money
flowchart LR
A["Customer Segments
60,000 employees
50 countries"] --> B["Three Core Businesses"]
B --> C["Biotechnology
Bioprocessing & Discovery"]
B --> D["Life Sciences
Instruments & Consumables"]
B --> E["Diagnostics
Clinical & Molecular"]
C --> F["Product Sales
$24.6B revenue"]
D --> F
E --> F
F --> G["Recurring Revenue
$20.1B, 82%"]
F --> H["Nonrecurring Revenue
$4.4B, 18%"]
G --> I["Operating Margin
19.1%, Operating CF $6.4B"]
H --> I
I --> J["DBS Continuous
Improvement Culture"]
J --> K["R&D & Talent
Investment"]
K --> C
K --> D
K --> E
I --> L["Capital for
Acquisitions"]
L --> C
L --> D
L --> E
Five years of financial data tell a story with two distinct chapters. From 2021 to 2022, revenue rose from $24.8 billion to $26.6 billion, driven in part by enormous demand for COVID-related diagnostics and vaccine manufacturing tools. Free cash flow, the cash left after paying for the upkeep and expansion of the business, reached $7.4 billion in 2022. Then the tide went out.
Annual Revenue 2021 to 2025 ($ billions)
Revenue peaked in 2022 then fell sharply as pandemic-era demand faded. 2025 showed the first meaningful recovery, with total sales rising 3.0% year over year.
When pharmaceutical companies finished stockpiling bioprocessing supplies after the pandemic, they dramatically cut orders. This inventory correction hit the Biotechnology segment hardest. Biotechnology revenue fell from $7.2 billion in 2023 to $6.8 billion in 2024, before recovering to $7.3 billion in 2025. Free cash flow dropped from $7.4 billion in 2022 all the way to $5.3 billion in 2025. That is a meaningful decline. Net debt has stayed elevated, ranging between $12.5 billion and $13.9 billion across the last three years, reflecting the weight of major acquisitions including the $5.7 billion purchase of Abcam in 2023.
$5.3B
Free cash flow in 2025, down from $7.4B at the 2022 peak
The Diagnostics segment has been the steadiest part of the business. It generated $9.9 billion in revenue in 2025 with a 26.7% operating profit margin, essentially flat with 2024. Hospitals keep running tests regardless of the economic cycle, which gives this segment a reliable floor. The Life Sciences segment is the weakest right now. Its operating profit margin collapsed from 16.9% in 2023 to 7.1% in 2025, hurt by impairment charges, lower demand from emerging biotech companies, and reduced government research funding. That compression is a serious signal worth watching.
16.9%
Life Sciences operating margin 2023
7.1%
Life Sciences operating margin 2025
The Life Sciences segment's profitability was cut by more than half in two years, driven by impairment charges, lower funding at biotech and academic customers, and weaker demand for equipment.
The 2025 recovery in Biotechnology was led by consumables demand from large pharmaceutical companies and contract manufacturers, particularly for monoclonal antibody production. That is an encouraging sign. But the recovery is still fragile. Core sales in the Life Sciences segment declined 1.5% in 2025. China, which represents 11% of total sales, is applying price controls through government procurement programs, and that is already pulling Diagnostics pricing down in that market.
2023
crisis
The Post-Pandemic Correction
After pharmaceutical companies massively over-ordered bioprocessing supplies during the COVID vaccine boom, they spent 2023 and 2024 burning through that inventory instead of placing new orders. This hit Danaher's Biotechnology segment hard, dropping its revenue by $413 million between 2022 and 2024. The segment only began recovering in 2025. At the same time, Danaher spun off its environmental business as Veralto in September 2023 and absorbed the $5.7 billion Abcam acquisition, adding complexity and debt at exactly the wrong moment in the cycle.
Several documented risks deserve attention. The company earns 59% of its sales outside the United States, and 11% specifically from China. Chinese government price controls are already forcing Danaher to cut prices in its Diagnostics segment. Currency swings added or subtracted roughly 1% from reported sales in both 2024 and 2025, which matters at this scale. Tariffs imposed since early 2025 cost the company less than $300 million in incremental costs during the year, and while management largely offset that impact, the situation remains unresolved as the U.S. government pursues new tariff authority.
What is a consumables business?
Many of Danaher's products work in two parts. First, a customer buys an expensive instrument or machine. Then, to keep using it, they must keep buying the specific chemicals, cartridges, filters, or reagents that only work with that machine. Those repeat purchases are called consumables. Because customers are locked into a particular system once they have built their lab or hospital workflow around it, consumables revenues tend to be very predictable and recurring.
Cepheid, Danaher's molecular diagnostics brand, faced public pressure in 2023 over the high price of its tuberculosis test cartridges. Author John Green made a widely viewed video about it, and Danaher subsequently lowered the price of one tuberculosis test by 20%. This episode illustrates a real tension in the business model. Products sold into global health settings, where governments and aid organizations pay the bills, are vulnerable to political and reputational pressure on pricing. The company's 10-K explicitly lists government reimbursement cuts as a high-severity risk, noting that Medicare, Medicaid, and comparable programs outside the U.S. are all moving to pay less for healthcare products.
59%
Share of 2025 sales from outside the United States, creating significant exposure to currency swings, trade policy, and foreign government pricing decisions
There is also a pending acquisition to watch. Danaher is trying to acquire Masimo Corporation, and antitrust regulators in the U.S. and other countries could block or delay the deal. If that happens, Danaher would have spent resources on a transaction that added nothing to its business. Meanwhile, the company spent $1.6 billion on research and development in 2025, including on artificial intelligence tools embedded in diagnostic and life sciences products. The 10-K notes that AI carries additional risks, including flawed algorithms, biased data, and concerns about job displacement, any of which could damage the company's reputation.
Danaher reorganized and integrated certain businesses within its Life Sciences segment during the third quarter of 2025 to better serve customers in new market segments. Reorganizations like this can be signs of genuine strategic sharpening, or they can signal that performance in those areas has disappointed management. The impairment charges that hit Life Sciences in 2025 suggest the latter played a role.
The gross margin has held in a fairly tight band across five years, between 58.7% and 61.4%, which reflects the durable pricing power that comes with selling specialized consumables that customers cannot easily substitute. But operating cash flow has declined from $8.5 billion in 2022 to $6.4 billion in 2025. That gap between gross margin stability and cash flow decline points to rising costs below the gross profit line, including higher selling and administrative expenses, impairment charges, and the amortization burden from past acquisitions.
$13.8B
Net debt at end of 2025, reflecting years of large acquisitions including Abcam for $5.7B in 2023 and Aldevron for $9.6B in 2021
The Bet
Danaher's Biotechnology segment, which supplies the filters, media, and single-use equipment that pharmaceutical companies need to manufacture biological drugs, must keep growing as demand for monoclonal antibodies, cell therapies, and gene therapies expands. The 2023 and 2024 inventory correction was a temporary pause, not a structural decline in demand. If that assumption is right, consumables volumes in bioprocessing recover and grow steadily, the Life Sciences segment stabilizes as funding returns to academic and emerging biotech customers, and the cash flow engine rebuilds. If biological drug manufacturing hits a longer plateau, or if funding to research institutions stays constrained, the recovery that 2025 hinted at does not materialize and the debt load from years of acquisitions becomes a heavier burden.
Open question
The Biotechnology segment showed a genuine recovery in 2025, with core sales up 6.5% driven by consumables demand from large pharmaceutical and contract manufacturing customers. But the Life Sciences segment is still shrinking in core terms, government research funding is under pressure, and China is actively cutting what it pays for diagnostic products. Is the 2025 Biotechnology rebound the start of a durable multi-year recovery in bioprocessing demand, or is it a one-year bounce that leaves the Life Sciences weakness and the debt load from Aldevron and Abcam as the defining story of the next several years?
Compiled · 10-K · FY2025
Healthcare Reimbursement and Pricing
Government programs like Medicare and Medicaid, which pay for many healthcare products the company sells, are reducing how much they will pay. The company gets 59% of sales from outside the U.S., where countries like China are using price controls to lower medical product costs. If customers cannot get paid enough by insurance companies and governments, they will buy fewer of the company's products or demand lower prices.
Product Development and Innovation
The company must constantly create new products with better technology to stay competitive and avoid becoming obsolete. If new products fail to work as promised, do not get approved by regulators, or patients and doctors do not use them, the company wastes money on research and development without earning sales. New AI-based products carry additional risks including flawed algorithms, biased data, and potential job displacement concerns that could hurt the company's reputation.
Pending Acquisition Risk
The company is trying to buy Masimo Corporation, but antitrust regulators in the U.S. and other countries might block or delay the deal with costly conditions. If the acquisition fails or takes much longer than expected, the company's growth plans could be damaged and it may have wasted resources on the deal.
International Operations and China Exposure
The company generates 11% of sales from China and 59% from outside the U.S. Chinese government policies on price controls, trade restrictions, and intellectual property protection could severely harm profits. Currency changes, military conflict, and political instability in countries where the company operates could disrupt manufacturing and sales.
Cybersecurity and Data Breaches
The company operates products and systems that connect to hospitals, patient records, and the internet. A major cyberattack or data breach could steal patient information, disrupt operations, cause product recalls, damage reputation, and result in huge fines under privacy laws like HIPAA and GDPR. The increasing use of AI in the company's products creates new cybersecurity vulnerabilities.
10-K Item 1A · Risk Factors
